Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 360

1.

Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors.

Papamichail M, Ali A, Pizanias M, Peddu P, Karani J, Heaton N.

Korean J Hepatobiliary Pancreat Surg. 2016 Aug;20(3):116-20. doi: 10.14701/kjhbps.2016.20.3.116. Epub 2016 Aug 29.

2.

Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours.

Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Holzner B, Virgolini I.

Health Qual Life Outcomes. 2016 Sep 10;14(1):127. doi: 10.1186/s12955-016-0527-2. Review.

3.

Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.

Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z.

BMC Gastroenterol. 2016 Sep 9;16:111. doi: 10.1186/s12876-016-0505-5.

4.

Complications from carcinoid syndrome: review of the current evidence.

Mota JM, Sousa LG, Riechelmann RP.

Ecancermedicalscience. 2016 Aug 8;10:662. doi: 10.3332/ecancer.2016.662. eCollection 2016. Review.

5.

Management of gastric and duodenal neuroendocrine tumors.

Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S.

World J Gastroenterol. 2016 Aug 14;22(30):6817-28. doi: 10.3748/wjg.v22.i30.6817. Review.

6.

Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype.

Maggi EC, Trillo-Tinoco J, Struckhoff AP, Vijayaraghavan J, Del Valle L, Crabtree JS.

Oncogenesis. 2016 Aug 22;5(8):e257. doi: 10.1038/oncsis.2016.58.

7.

Duodenal neuroendocrine tumor and the onset of severe diabetes mellitus in a US veteran.

Murray L, Haley C, Berry-Cabán CS, Toledo A.

SAGE Open Med Case Rep. 2016 Feb 15;4:2050313X15624530. doi: 10.1177/2050313X15624530. eCollection 2016.

8.

Neuroendocrine Tumors of the Large Intestine: Clinicopathological Features and Predictive Factors of Lymph Node Metastasis.

Kojima M, Ikeda K, Saito N, Sakuyama N, Koushi K, Kawano S, Watanabe T, Sugihara K, Ito M, Ochiai A.

Front Oncol. 2016 Jul 18;6:173. doi: 10.3389/fonc.2016.00173. eCollection 2016.

9.

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.

Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF.

Br J Cancer. 2016 Aug 23;115(5):564-70. doi: 10.1038/bjc.2016.229. Epub 2016 Aug 2.

PMID:
27482646
10.

Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution.

Yang M, Tan CL, Zhang Y, Ke NW, Zeng L, Li A, Zhang H, Xiong JJ, Guo ZH, Tian BL, Liu XB.

Medicine (Baltimore). 2016 Jul;95(28):e4213. doi: 10.1097/MD.0000000000004213.

11.

(18)F-FDG PET/CT Imaging of Primary Hepatic Neuroendocrine Tumor.

Mitamura K, Yamamoto Y, Tanaka K, Sanomura T, Murota M, Nishiyama Y.

Asia Ocean J Nucl Med Biol. 2015 Winter;3(1):58-60.

12.

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET).

Wong MH, Chan DL, Lee A, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N.

PLoS One. 2016 Jun 30;11(6):e0158140. doi: 10.1371/journal.pone.0158140. eCollection 2016.

13.

Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature.

Krug S, Boch M, Rexin P, Pfestroff A, Gress T, Michl P, Rinke A.

BMC Res Notes. 2016 Jun 27;9:326. doi: 10.1186/s13104-016-2132-1.

14.

Update on management of midgut neuroendocrine tumors.

Mehrvarz Sarshekeh A, Halperin DM, Dasari A.

Int J Endocr Oncol. 2016 May;3(2):175-189. Epub 2016 Apr 8.

PMID:
27347369
15.

Paraneoplastic Cushing's syndrome associated with bronchopulmonary carcinoid tumor in youth: A case report and review of the literature.

Li WY, Liu XD, Li WN, Dong SY, Qu XH, Gong SL, Shao MR, Zhang L.

Oncol Lett. 2016 Jul;12(1):69-72. Epub 2016 May 16.

PMID:
27347101
Free PMC Article
16.

The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012.

Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L.

ISRN Hepatol. 2013 Feb 14;2013:702167. doi: 10.1155/2013/702167. eCollection 2013. Review.

17.

Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report.

Bellorin O, Shuchleib A, Halevi AE, Aksenov S, Saldinger PF.

Int J Surg Case Rep. 2016;25:62-5. doi: 10.1016/j.ijscr.2016.06.008. Epub 2016 Jun 16.

18.

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era.

Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS.

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.

19.

Neuroendocrine Cancer of Rectum Metastasizing to Ovary.

Amin SV, Kumaran A, Bharatnur S, Vasudeva A, Udupa K, Venkateshiah DB, Bhat ST.

Case Rep Oncol Med. 2016;2016:7149821. doi: 10.1155/2016/7149821. Epub 2016 May 18.

20.
Items per page

Supplemental Content

Write to the Help Desk